Wednesday, 12 September 2007

Dr. Sandeep S Davé to Join Med Biogene Lymphoma Collaboration Team

Today Med BioGene Inc. (MBI: TSX-V) announced world renowned expert in the research of gene expression profiling of lymphoma, Sandeep S. Davé, M.D. from Duke University will be directly involved with the development of their LymphExpress DxTM product. This announcement follows the research collaboration and option agreement that Med BioGene and Duke University penned last March.

Highlights from Dr. Dave’s career include the following:

  • Assistant Professor in the Institute of Genome Sciences and Policy and in the Department of Medicine’s Division of Medical Oncology at Duke University.

  • Formerly a postdoctoral fellow at the laboratory of Louis Staudt at the National Cancer Institute.

  • Involved in translational research aimed at using gene expression profiling to understand the role of differentially activated molecular pathways in non-Hodgkin lymphoma.

  • Published articles include:
    “Molecular Diagnosis of Burkitt’s lymphoma” –
    New England Journal of Medicine.
    “Prediction of Survival in Follicular Lymphoma based on Molecular Features of Tumor-Infiltrating Immune Cells” – New England Journal of Medicine.

  • Received Doctorate from Northwestern University. His fellowship was in hematology and medical oncology at the National Institutes of Health.

In recognition of this announcement Dr. Davé said, “I am very excited to work with Med BioGene and to expand upon the work that I undertook at the National Cancer Institute. Gene expression profiling has demonstrated that lymphoma types that were previously regarded as homogenous can harbor subgroups that are dramatically different in their biology and responses to therapy. Such studies could form the basis for risk stratification and tailored therapies that are most likely to benefit molecularly defined subgroups of patients.”

With the recent attention from cancer research heavy weights like Dr. Davé and Duke University, keep an eye on this one.

Click here to read the release.